Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAxel Hauschild, Chris Miller, Laurent Mortier et al.|BMC Cancer|2017Cited by 412
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trialNicole Basset‐Séguin, Johan Hansson, Axel Hauschild et al.|European Journal of Cancer|2017Cited by 284
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE studyJohan Hansson, Axel Hauschild, Karen Bartley et al.|European Journal of Dermatology|2018Cited by 26
Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).Johan Hansson, Nicole Basset‐Séguin, Axel Hauschild et al.|Journal of Clinical Oncology|2016Cited by 7